U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H16N2O4
Molecular Weight 264.2771
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHENYLACETYLGLUTAMINE

SMILES

NC(=O)CC[C@H](NC(=O)CC1=CC=CC=C1)C(O)=O

InChI

InChIKey=JFLIEFSWGNOPJJ-JTQLQIEISA-N
InChI=1S/C13H16N2O4/c14-11(16)7-6-10(13(18)19)15-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H2,14,16)(H,15,17)(H,18,19)/t10-/m0/s1

HIDE SMILES / InChI

Molecular Formula C13H16N2O4
Molecular Weight 264.2771
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Antineoplaston (Phenylacetylglutamine) is the amino acid acetylation product of phenylacetate (or phenylbutyrate after beta-oxidation). The chemical structure of Antineoplaston AS2-5 corresponds to phenylacetylglutamine. Two synthetic derivatives of Antineoplaston A10 were named Antineoplaston AS2-1 and AS2-5. All antineoplaston formulations were submitted for Phase I clinical studies in advanced cancer patients. The treatment was free from significant side-effects and resulted in objective response in a number of advanced cancer cases. Antineoplastons are an experimental cancer therapy developed by S.R. Burzynski, MD, PhD. Chemically, antineoplastons are a mixture of amino acid derivatives, peptides, and amino acids found in human blood and urine. The developer originally isolated antineoplastons from human blood and later found the same peptides in urine. Urine was subsequently used because it was less expensive and easier to obtain. Since 1980, antineoplastons have been synthesized from commercially available chemicals at the Burzynski Research Institute. According to the developer, antineoplastons are part of a biochemical surveillance system in the body and work as "molecular switches." For the developer, cell differentiation is the key to cancer therapy. At the molecular level, abnormal cells that are potential cancer cells need to be "switched" to normal mode. Antineoplastons are the surveillance system that directs cancer cells into normal channels of differentiation. According to statements published by the developer, people with cancer lack this surveillance system because they do not have an adequate supply of antineoplastons.

Approval Year

PubMed

PubMed

TitleDatePubMed
Phenylacetylglutamine may replace urea as a vehicle for waste nitrogen excretion.
1991 Feb

Sample Use Guides

Toxicology studies of Antineoplaston AS2-5 injections involved 13 patients diagnosed with 15 types of neoplastic disease, including: lung cancer, 3 cases; breast, 3 cases; colon, 2 cases; and single cases of cancer of the larynx, prostate, stomach, pancreas, malignant fibrohistiocytoma, embryonal teratoma and lymphocytic lymphoma. Antineoplaston AS2-5 was injected i.v. daily through subclavian vein catheter in divided doses. The treatment was administered from 41 to 436 days. The highest dosage given was 167.6 mg/kg/24 h.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:53:51 GMT 2023
Edited
by admin
on Fri Dec 15 17:53:51 GMT 2023
Record UNII
92358I79RG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PHENYLACETYLGLUTAMINE
Systematic Name English
ANTINEOPLASTON AS2-1 COMPONENT PHENYLACETYLGLUTAMINE
Common Name English
PHENYLACETYL-L-GLUTAMINE
Systematic Name English
Phenylacetylglutamine [WHO-DD]
Common Name English
NSC-203800
Code English
PHENYLACETYLGLUTAMINE [MI]
Common Name English
L-GLUTAMINE, N2-(PHENYLACETYL)-
Systematic Name English
ASTUGENAL COMPONENT PHENYLACETYLGLUTAMINE
Common Name English
ANTINEOPLASTON AS 2-1 COMPONENT PHENYLACETYLGLUTAMINE
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 189804
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
FDA ORPHAN DRUG 267408
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
Code System Code Type Description
CHEBI
17884
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
PRIMARY
NCI_THESAURUS
C1613
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
NO STRUCTURE GIVEN
CHEBI
8087
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
PRIMARY
FDA UNII
92358I79RG
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
PRIMARY
NSC
203800
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
PRIMARY
EPA CompTox
DTXSID90182324
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
PRIMARY
MERCK INDEX
m11916
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
PRIMARY
WIKIPEDIA
PHENYLACETYLGLUTAMINE
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
PRIMARY
CAS
28047-15-6
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
PRIMARY
PUBCHEM
92258
Created by admin on Fri Dec 15 17:53:51 GMT 2023 , Edited by admin on Fri Dec 15 17:53:51 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> METABOLITE
Formed in the liver and excreted in the urine responsible for the reduction of ammonia in the blood.
MAJOR
URINE
Related Record Type Details
ACTIVE MOIETY